GleamWall
中文EN

PTN PALATIN TECHNOLOGIES INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 911216 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-276.9%
TTM EPS YoY-4.0%
Revenue 3-yr CAGR-61.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,354.1%
Net margin-5,261.5%
FCF margin—
EBITDA margin-5,335.2%

Returns

ROE-1,495.4%
ROA-271.7%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets57.1%
Debt / equity0.00x
Current ratio1.67x
Interest coverage-2,873.67x

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-36.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue$8.83M$0
R&D expense$12.37M$14.90M
SG&A expense$9.48M$7.81M
Operating income-$8.67M-$17.46M
Interest expense$6,726$15,025
Income tax-$8.38M-$17.31M
Net income-$8.38M-$17.31M
EBITDA-$8.61M-$17.20M
EPS (basic)-2.96-32.15
EPS (diluted)-2.96-32.15
Weighted avg. shares (diluted)2.83M538,348
Balance sheet
Cash & equivalents$7.49M$9.53M
Receivables$300,770$0
Current assets$8.16M$2.92M
PP&E, net$118,064$129,444
Total assets$8.52M$3.27M
Current liabilities$1.77M$8.01M
Total liabilities$1.84M$8.04M
Shareholders' equity$6.69M-$4.78M
Shares outstanding1.78M929,597
Cash flow statement
Operating cash flow-$13.53M-$21.31M
Capital expenditure$51,299$0
Free cash flow-$13.58M-$21.31M
Investing cash flow-$51,299$3.13M
Financing cash flow$18.51M$11.21M
Depreciation & amortization$62,679$258,917
Stock-based compensation$1.33M$1.38M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.